Aligos Therapeutics, Inc. (NASDAQ:ALGS) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Aligos Therapeutics, Inc. (NASDAQ:ALGS) have been given a consensus recommendation of “Moderate Buy” by the seven research firms that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, five have given a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $38.50.

Several equities analysts have weighed in on the company. HC Wainwright reaffirmed a “buy” rating on shares of Aligos Therapeutics in a report on Monday, August 10th. Lake Street Capital started coverage on Aligos Therapeutics in a research report on Thursday, May 28th. They issued a “buy” rating and a $45.00 price target on the stock. Weiss Ratings raised Aligos Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Wall Street Zen raised Aligos Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Sunday, May 17th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Aligos Therapeutics in a research report on Friday, May 29th.

Aligos Therapeutics Stock Up 3.6%

Shares of Aligos Therapeutics stock opened at $6.67 on Friday. The stock has a market capitalization of $41.62 million, a price-to-earnings ratio of -0.91 and a beta of 2.31. Aligos Therapeutics has a twelve month low of $3.98 and a twelve month high of $13.69. The company has a 50-day simple moving average of $5.67 and a two-hundred day simple moving average of $6.33.

Aligos Therapeutics (NASDAQ:ALGS) last announced its earnings results on Thursday, August 6th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.09) by $0.95. The firm had revenue of $27.78 million for the quarter, compared to analyst estimates of $24.68 million. Aligos Therapeutics had a negative net margin of 241.01% and a negative return on equity of 160.72%. On average, sell-side analysts anticipate that Aligos Therapeutics will post -6.81 earnings per share for the current fiscal year.

Institutional Trading of Aligos Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Rockefeller Capital Management L.P. increased its stake in Aligos Therapeutics by 900.0% in the fourth quarter. Rockefeller Capital Management L.P. now owns 10,000 shares of the company’s stock valued at $93,000 after acquiring an additional 9,000 shares during the last quarter. Susquehanna International Group LLP acquired a new position in Aligos Therapeutics during the third quarter valued at approximately $99,000. XTX Topco Ltd acquired a new position in Aligos Therapeutics during the second quarter valued at approximately $100,000. HRT Financial LP bought a new stake in Aligos Therapeutics during the fourth quarter worth $106,000. Finally, DRW Securities LLC bought a new stake in Aligos Therapeutics during the fourth quarter worth $111,000. Institutional investors own 60.43% of the company’s stock.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.